Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced Life Sciences, a biopharmaceutical company engaged in the discovery, development and commercialisation of new drugs in the therapeutic areas of infection, oncology and respiratory diseases, has expanded its collaboration with the US Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.
Subscribe to our email newsletter
As per the expanded agreement, Restanza’s in-vitro activity against Neisseria gonorrhoeae and other key STI’s is expected to be assessed, to advance Restanza into clinical development in government-sponsored clinical trials.
Advanced Life Sciences said that the activity of Restanza has been evaluated against 148 N gonorrhoeae isolates and demonstrated in-vitro activity as measured by minimal inhibitory concentration (MIC).
Restanza was comparable in activity to azithromycin and ciprofloxacin and superior to erythromycin and clarithromycin, the antibiotics commonly used to treat gonorrhea infections.
Michael Flavin, CEO of Advanced Life Sciences, said: “We believe that Restanza has proven itself as a treatment for gonorrhea and other sexually transmitted infections and we are excited to expand our partnership with the US Government beyond biodefense to further explore its therapeutic activity.
“Restanza’s activity against community-acquired, bioterror and other bacterial pathogens make it an ideal candidate for government-supported development. We look forward to partnering with the government to address this health challenge.”